BioArctic Nomination Committee Proposes Strengthened Board Ahead of 2026 AGM

BioArctic AB Class B ( ($SE:BIOA.B) ) has issued an announcement.

BioArctic’s Nomination Committee has proposed an eight-member board without deputies for election at the company’s Annual General Meeting on May 28, 2026, including the re-election of six current directors and chairperson Eugen Steiner. The committee also proposes adding dementia specialist Philip Scheltens and H&M executive Linda Nilsson, with Nilsson replacing outgoing director Pär Gellerfors as representative of major shareholder Ackelsta AB, signaling a blend of scientific depth and operational expertise on the board.

Scheltens brings extensive global experience in Alzheimer’s research, clinical trials and dementia policy, while Nilsson contributes broad strategic and financial leadership from a large international consumer business. The Nomination Committee, appointed by shareholders representing about 57 percent of shares and 83 percent of votes, aims to strengthen BioArctic’s governance and board competence as it advances its neuroscience portfolio, with full details of the proposals to be published ahead of the AGM on the company’s website.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK355.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

More about BioArctic AB Class B

BioArctic AB is a Swedish biopharmaceutical company listed on Nasdaq Stockholm that focuses on developing treatments in neuroscience, particularly for neurodegenerative diseases such as Alzheimer’s. The company operates in close collaboration with academic institutions and industrial partners, targeting disease-modifying therapies for conditions with high unmet medical need.

Average Trading Volume: 197,830

Technical Sentiment Signal: Strong Buy

Current Market Cap: SEK28.14B

For detailed information about BIOA.B stock, go to TipRanks’ Stock Analysis page.